MedCity News April 25, 2021
As researchers and clinicians understand and embrace the advanced insights genetic and genomic testing can deliver, the industry is poised to dramatically reduce the incidence and mortality associated with cancers.
Cancer is the second leading cause of death in the U.S., according to the Center for Disease Prevention and Control (CDC), behind heart disease. Within the universe of cancers, breast is the most common, followed by lung, prostate and colorectal, according to the National Cancer Institute (NCI).
Treatment costs have skyrocketed. According to one report published by The Mesothelioma Center, the burden of cancer care in the U.S. topped $150 billion in 2018, four times higher than treatment for other conditions. The most expensive forms of cancer are lung, colorectal,...
Today's Sponsors
Today's Sponsor